Beijing has set ambitious new five-year targets to boost its global presence, including at least five pharmaceutical products with annual global sales surpassing US$1 billion by 2030. Jefferies' head of Asia healthcare research Cui Cui noted that Chinese biopharmaceutical companies' competitive efficiency and speed would drive global commercialization, making the goal achievable.